APP and Alzheimer disease: Initially, these inhibitors were simple peptidomimetics (e.g., TSAs), but pharmaceutical companies quickly developed compounds with much better drug-like properties that allowed in vivo testing for the ability to lower Aβ in the brains of transgenic AD mice (e.g., expressing FAD-mutant APP and presenilin).